WEST LAFAYETTE, Ind., Oct. 30, 2017 (GLOBE NEWSWIRE) -- Endocyte, Inc., (NASDAQ:ECYT) announced today that the company will host a conference call on Monday, Nov. 6th, at 4:30 p.m. EST to discuss its third quarter financial results and provide an operational update.
Investors and the general public are invited to listen to a live webcast of the call, which can be accessed in the Investors & News section of the Company's website at www.endocyte.com or by dialing (877) 845-0711 (U.S./Canada) or (760) 298-5081 (International).
The webcast will be recorded and available on the Company's website for 90 days following the call.
Endocyte is a biopharmaceutical company and leader in
developing targeted therapies for the treatment of cancer. Endocyte uses drug conjugation technology to create novel therapeutics and companion imaging agents for personalized targeted therapies. The company's agents actively target receptors that are over-expressed on diseased cells relative to healthy cells, such as prostate specific membrane antigen (PSMA) in prostate cancer. This targeted approach is designed to safely enable the delivery of highly potent drug payloads. The companion imaging agents are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment. For additional information, please visit Endocyte's website at www.endocyte.com.
Stephanie Ascher, Stern Investor Relations, Inc., (212) 362-1200, email@example.com
Source: Endocyte, Inc.
News Provided by Acquire Media